Ingenium Therapeutics Secures 5.3 Billion Won in Series A Funding to Advance Natural Killer Cell Therapies and Global Expansion
Ingenium Therapeutics, a South Korean biotech company specializing in the development of next-generation Natural Killer (NK) cell therapies and related immunotherapies,...